BCM
RVPH

BluePointe Capital Management’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

BluePointe Capital Management’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$45K Buy
2,359
+1,840
+355% +$57.8K 0.02% 128
2024
Q4 		$18.8K Hold
519
– – 0.01% 94
2024
Q3 		$14.9K Hold
519
– – 0.01% 88
2024
Q2 		$13.3K Hold
519
– – 0.01% 86
2024
Q1 		$39.2K Hold
519
– – 0.03% 87
2023
Q4 		$53.4K Buy
+519
New +$46.6K 0.04% 87

Other funds holding RVPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

BluePointe Capital Management's RVPH Position: Q1 2025 in Review

BluePointe Capital Management increased its REVIVA PHARMA HLDGS INC (RVPH) stake by 355% in Q1 2025, buying an estimated $57.8K and bringing the position to 2,359 shares worth $45K. The position accounts for 0.02% of the portfolio, ranked #128.

BluePointe Capital Management first reported a position in RVPH in Q4 2023 and has held it in 6 quarters since. The position peaked at $53.4K in Q4 2023. 48 funds tracked by Wall St. Rank hold RVPH as of Q1 2025.

  • BluePointe Capital Management held 2,359 shares of REVIVA PHARMA HLDGS INC worth $45K as of Q1 2025.
  • BluePointe Capital Management bought 1,840 REVIVA PHARMA HLDGS INC shares in Q1 2025, an estimated $57.8K.
  • REVIVA PHARMA HLDGS INC made up 0.02% of BluePointe Capital Management's portfolio in Q1 2025, its #128 holding.
  • BluePointe Capital Management first reported a position in REVIVA PHARMA HLDGS INC in Q4 2023 and has held it in 6 quarters since.
  • BluePointe Capital Management's REVIVA PHARMA HLDGS INC position peaked at $53.4K in Q4 2023.
  • 48 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q1 2025.

Based on BluePointe Capital Management's 13F filing for Q1 2025, filed 2 May 2025.